Online inquiry

IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10445MR)

This product GTTS-WQ10445MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Cachexia research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10445MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15700MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ9389MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ4127MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BI-505
GTTS-WQ2498MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ1593MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ8369MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ15693MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ5405MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD58-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW